Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, was featured in the latest BioMedWire Podcast episode where CEO Christopher Schaber discussed the upcoming interim analysis of the Phase 3 FLASH2 study evaluating HyBryte for cutaneous T-cell lymphoma. Schaber noted strong blinded aggregate response rates above initial assumptions and outlined potential outcomes including early study completion or continued enrollment.
The CEO emphasized that upcoming interim and top-line data represent potentially transformational milestones that could support commercialization and partnership opportunities for the company. HyBryte, also known as SGX301 or synthetic hypericin sodium, is being developed as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, a rare form of cancer affecting the skin.
With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. The development represents a significant advancement in treating a rare disease with limited therapeutic options, potentially offering patients a new treatment modality with a favorable safety profile compared to existing therapies.
Beyond the immediate CTCL application, Soligenix is expanding synthetic hypericin into psoriasis treatment under the designation SGX302, demonstrating the platform's potential across multiple dermatological conditions. The company's pipeline also includes first-in-class innate defense regulator technology with dusquetide for inflammatory diseases including oral mucositis in head and neck cancer, and additional applications in Behçet's Disease.
Soligenix maintains a Public Health Solutions business segment that includes development programs for RiVax, a ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses such as Marburg and Ebola, and CiVax for COVID-19 prevention. These programs incorporate the company's proprietary heat stabilization platform technology known as ThermoVax and have been supported with government grant and contract funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX. BioMedWire is a specialized communications platform focused on biotechnology, biomedical sciences and life sciences sectors, operating as one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers comprehensive distribution and corporate communications solutions. For more information about BioMedWire, visit https://www.BioMedWire.com.
